Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry

Published by: Spectra Intelligence

Published: Jan. 1, 2006 - 124 Pages


Table of Contents



SPECTRA COMPENDIA

The World Market for Sexual Disorders, 2005-2012:

Traversing New Frontiers in Sexual Chemistry

List of Tables

List of Figures

Executive Summary

Objectives of the Report

Research Methodology

Chapter 1 Introduction to Sexual Disorders

Sexual Disorders

Prevalence of Sexual Dysfunction
Male Sexual Disorders
Sexual Desire Disorders
Male Erectile Dysfunction

Normal Erectile Function

Psychological Aspects of Male Erectile Dysfunction

Prevalence of Male Erectile Dysfunction

Therapeutics for Male Erectile Dysfunction

Priapism

Peyronie’s disease

Disorders of Ejaculation

Premature Ejaculation

Retarded Ejaculation

Retrograde Ejaculation

Female Sexual Dysfunction
Prevalence of Female Sexual Dysfunction
Specific Female Sexual Dysfunction Disorders

Disorders of Desire

Disorders of Arousal

Disorders of Lubrication

Persistent Sexual Arousal Syndrome

Disorders of Orgasm

Pain Disorders

Dyspareunia

Vulvodynia

Vaginismus

Chapter 2 The Sexual Disorders Pharmacotherapy Market

Market Data Synopsis - Sexual Disorders

Sexual Disorders: Market Overview
Market Analysis for Sexual Disorder Pharmacotherapeutics
Testosterone Replacement
Erectile Dysfunction

Female Sexual Disorders

Male Sexual Disorders
Androgen Deficiency and Disorders of Desire
The Andropause

Product Market Analysis for Androgen Deficiency and Disorders of Desire

Columbia Labs/Ardana

Sales Estimates and Market Outlook

Organon

Sales Estimates and Market Outlook

Schering

Sales Estimates and Market Outlook

Solvay Pharmaceuticals

Sales Estimates and Market Outlook

Drugs in Research and Development for Androgen Deficiency and Andropause

Ascend Therapeutics

Ardana

GTx

Androgen Deficiency and Sarcopenia - A High-Growth Market Prospect

National Institute on Aging

Anastrozole/Testosterone

Androgen Supplementation

Testosterone and Human Growth Hormone

Zonagen

Future Considerations for Drugs to Treat Androgen Deficiencies Associated

with Sexual Disorders and Andropause

Erectile Dysfunction
Uprima/Ixense (Apomorphine) - Abbott/TAP Pharmaceuticals
Sales Estimates and Market Outlook

Levitra (Vardenafil) - Bayer/GlaxoSmithKline

Sales Estimates and Market Outlook

Cialis (Tadalafil) - Lilly/ICOS

Sales Estimates and Market Outlook

Viagra (Sildenafil); Caverject (Alprostadil) - Pharmacia/Pfizer

Sales Estimates and Market Outlook

Viridal/Edex (Alprostadil) - Schwarz

Sales Estimates and Market Outlook

Invicorp (Phentolamine Mesilate/Vasoactive Intestinal Polypeptide) -

Senetek/Ardana

Sales Estimates and Market Outlook

MUSE (Alprostadil) - Vivus

Sales Estimates and Market Outlook

Pipeline Focus - Avanafil

Future Considerations and Market Outlook for Drugs to Treat

Erectile Dysfunction

Pipeline Drugs and Market Prospects in the Sexual Disorder Market

Erectile Dysfunction Drug Pipeline

Prograf (Tacrolimus/FK506) - Astellas Pharma

Alprox-TD (Alprostadil) - NexMed/Schering

PT-141 - Palatin Technologies/King Pharmaceuticals

Emerging Sexual Disorder Therapy Areas
Premature Ejaculation
Neuronal Mechanism of Premature Ejaculation

Drugs in Development for Premature Ejaculation

Dapoxetine - ALZA/Johnson & Johnson

Investigational Drug - Pfizer

BIO301 - Enhance Biotech/Bioaccelerate

NM100061 - NexMed

Future Considerations and Market Outlook for Drugs to Treat

Premature Ejaculation

Female Sexual Disorders
A High-Growth Market Opportunity?
Drugs in Development for Female Sexual Disorders

Intrinsa (Testosterone Patch) - Proctor & Gamble Pharmaceuticals/

Watson Pharma

Tostrelle (Testosterone Gel) - Cellegy Pharmaceuticals

Androgel (Testosterone Gel) - Beersheva Mental Health Center, Israel

LibiGel (Testosterone Gel) - Antares Pharma/Biosante Pharmaceuticals

PT-141 - Palatin Technologies/King Pharmaceuticals

Alista (Alprostadil); Testosterone MDTS - Vivus/Acrux

Femprox Cream (Alprostadil) - NexMed

Future Considerations and Market Outlook for Drugs to Treat

Female Sexual Dysfunction

Chapter 3 Drugs in Research and Development

Male Sexual Disorders

Research and Development Overview

Female Sexual Dysfunction

Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

Sexual Disorders: Therapy Area Forecasts

Market Share of Male Sexual Disorder Market

Comparative Analysis: Product Sales

Prospect Mining

Androgen Deficiency/Testosterone Replacement

Erectile Dysfunction and Premature Ejaculation

Female Sexual Dysfunction

Therapy Area Forecasts: 2012 and 2020

Chapter 5 Report Synopsis

Male Sexual Disorders - Key Data Points

Female Sexual Disorders - Key Data Points

Reference Sources

List of Tables

Table 1.1 Male and Female Sexual Dysfunction Disorders

Table 1.2 Medical and Surgical Conditions Associated with Erectile Dysfunction

Table 1.3 Therapeutic Options for Erectile Dysfunction

Table 2.1 Global Sales (US$) & Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012

Table 2.2 Marketed Drugs for Androgen Deficiency and Erectile Dysfunction, 2005

Table 2.3 Symptoms of Andropause

Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Striant, 2005-2012

Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Organon’s Androgen Replacement Therapy Products, 2005-2012

Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Schering’s Andrology Product Portfolio, 2005-2012

Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Androgel, 2005-2012

Table 2.8 Drugs in Development for Androgen Deficiency and Andropause, 2005

Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Uprima/Ixense, 2005-2012

Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Levitra, 2005-2012

Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Cialis, 2005-2012

Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Erectile Dysfunction Product Portfolio, 2005-2012

Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Viridal/Edex, 2005-2012

Table 2.14 Estimated Sales (US$) and Annual Growth (%) of Invicorp, 2005-2012

Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Muse, 2005-2012

Table 2.16 Drugs in Development for Male Erectile Dysfunction, 2005

Table 2.17 Drugs in Development for Premature Ejaculation, 2005

Table 2.18 Drugs in Development for Female Sexual Dysfunction, 2005

Table 3.1 Drugs in Development for Male Androgen Deficiency and Andropause, 2005

Table 3.2 Drugs in Development for Male Erectile Dysfunction and Premature Ejaculation, 2005

Table 3.3 Drugs in Development for Female Sexual Dysfunction, 2005

Table 4.1 Global Market for Male Sexual Disorders (US$m), 2004-2012

Table 4.2 Therapy Area Forecasts for the Global Sexual Disorders Drug Market: 2012 and 2020

List of Figures

Figure 2.1 Estimated Sales (US$) and Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012

Figure 2.2 Estimated Growth and Global Market Share of Leading Drugs for Male Sexual Disorders, 2005 & 2012

Figure 4.1 Therapy Area Forecasts for Male Testosterone Replacement and Erectile Dysfunction, 2005 & 2012 (US$m)

Figure 4.2 Market Share of Male Testosterone Replacement (Desire/Arousal Conditions) and Erectile Dysfunction Therapy Areas, 2005 & 2012

Figure 4.3 Comparative Analysis of Leading Testosterone Replacement Therapies and Erectile Dysfunction Products, 2004-2012 (US$m)

Figure 4.4 Key Testosterone Replacement Drug Prospects in the Development Pipeline, 2005

Figure 4.5 Key Erectile Dysfunction and Premature Ejaculation Drug Prospects in the Development Pipeline, 2005

Figure 4.6 Key Female Sexual Dysfunction Drug Prospects in the Development Pipeline, 2005

Abstract

The sexual disorder pharmacotherapy market is dominated by drugs indicated for erectile dysfunction which commands an estimated 78% of the total sexual disorder market valued at US$3 billion. Significant market opportunities are evident for the expansion of androgenic therapies to treat sexual disorders in new population groups such as in women with hypoactive sexual desire disorder and in male andropause. Furthermore, new drugs are on course to redefine the landscape of sexual medicine by offering novel therapies for premature ejaculation and specific desire-arousal disorders. Emerging drug treatments targeting the unmet needs of women with sexual disorders are poised to revolutionize the market for sexual dysfunction, and Spectra predicts that the female sexual dysfunction sector may outperform those therapies indicated for male sexual disorders within a decade of availability. However, as a relatively young and controversial therapy area, new drugs for sexual disorders are subject to intense regulatory scrutiny and navigating through the drug approval process is challenging particularly for new sexual disorder indications, which is evident from recent market authorization setbacks for Proctor & Gamble's Intrinsa for female hypoactive sexual desire disorder and Johnson & Johnson/Alza's Dapoxetine for premature ejaculation. However, in this report, The World Market for Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a dynamic, high-value therapy area estimated to exceed US$6.6 billion by 2012.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008